TORONTO, May 3, 2021 /PRNewswire/ - Maverix Private
Equity, a Toronto-based private equity firm which
recently announced an inaugural USD $500
million growth-fund, has today announced the addition of
Michael Wasserman as a Managing
Partner, joining Founder John
Ruffolo and Mark Maybank.
Michael is returning to Canada
after 17 years at H.I.G Capital Management, a leading global
private equity investment firm with more than $44 billion of equity
capital under management. Most recently, Michael was a
Managing Director of H.I.G. BioHealth Partners, the firm's
dedicated healthcare investment fund, where Michael sourced,
executed and managed a diverse investment portfolio of healthcare
business across stages, sectors and geographies. Michael
remains a Senior Advisor with H.I.G. In addition to his
firm-wide responsibilities, Michael will be leading Maverix's
investments in Healthcare and Wellness, one of the firm's core
investment themes.
"I could not be prouder to be coming home to join this talented
group of investors and entrepreneurs", said Michael Wasserman. "The progress and
evolution of the Canadian innovation ecosystem in recent years has
been nothing short of remarkable. Maverix is uniquely
positioned to help catalyze the growth of disruptive Canadian
businesses and global leaders and I am truly humbled and excited to
be part of this compelling effort."
In addition to Michael Wasserman,
Peter Hass has also joined Maverix
as Associate Partner. Peter will be leading investment deal
execution including financial modelling and leading due diligence.
Peter will also work closely with portfolio companies in
strategic and financial management as well as the evaluation of
organic and inorganic growth opportunities. Peter is an
experienced private equity investor, having formerly worked at both
Mattamy Asset Management and OMERS Growth Equity.
Finally, Jonathan Goodman,
co-founder, President and CEO of publicly traded Paladin Labs Inc.,
which was acquired in 2014 by Endo International In. (NASDAQ: ENDP)
for $3.2 billion will be joining the
Maverix Advisory board as its 6th member. The
Maverix Advisory Board represents a who's who of successful
Canadian entrepreneurs and business leaders, who share a similar
mission, to help build the next wave of disruptive Canadian
businesses.
Under Mr. Goodman`s leadership, $1.50 invested in Paladin at its founding was
worth $142 nineteen years later. The
same day that Paladin was sold, Mr. Goodman started a second
publicly-traded specialty pharmaceutical company, Knight
Therapeutics Inc. (TSX: GUD), which has now raised $685 million of equity in 5 rounds of financing
all at increasing valuations. Since inception in February 2014, Knight has generated over
$220 million of net income. For the
last 25 years, Mr. Goodman has devoted 15% of his time on
Tikkun Olam, which has included
fielding the largest team in the Province of Quebec for the Ride to Conquer Cancer for 7
consecutive years to filling Place des Arts for the Ted Wise
ORT/Jewish Education Gala for 6 consecutive years raising $10+
million to support Jewish education.
ABOUT MAVERIX PRIVATE EQUITY
Maverix Private Equity is a Toronto-based private
equity firm. It is led by an experienced and talented team with the
background, network, and track record necessary to successfully
execute on an investment strategy of technology-enabled growth and
disruption. Maverix is currently investing out
of its inaugural fund, the Maverix Growth Equity
Fund I, of USD$500M. Maverix
targets North American companies with rapidly growing
revenue and evidence of a profitable business model. Its
target cheque size is expected to average USD$50M for meaningful minority positions in
portfolio companies.
For more information on Product:
https://www.maverixpe.com
View original
content:http://www.prnewswire.com/news-releases/maverix-private-equity-announces-team-additions-301281565.html
SOURCE Maverix Private Equity